Background: Chlorhexidine (CHX) gluconate has remained the gold standard chemical plaque control agent till date, though, being associated with several disadvantages including its tendency to stain teeth and leading to irritation of soft tissues. To overcome these inherent disadvantages, there has been a surge of studies in the recent past to evaluate the efficacy of herbal mouthrinses as against CHX.
Objective: The present study was planned to compare the anti-plaque efficacy of Hi-Ora mouthrinse as against 0.12% CHX in patients with chronic gingivitis.
Materials And Methods: The present study was designed as a case-control study including 90 patients with chronic gingivitis who were divided into 3 groups including Group A in which 0.12% CHX was prescribed, Group B in which patients were prescribed Hi-Ora and Group C in which normal saline was prescribed after oral prophylaxis while the mean Gingival Index (GI) and Plaque Index (PI) scores were recorded on the 5 postprocedural day.
Results: The mean GI score in CHX group was found to be 0.70 ± 0.25 as against 0.66 ± 0.16 in Hi-Ora and 1.59 ± 0.55 in normal saline groups. Similarly, the mean PI score in CHX group was found to be 0.80 ± 0.31 as against 0.77 ± 0.30 in Hi-Ora and 1.86 ± 0.61 in normal saline groups.
Conclusions: The results of the present study suggested Hi-Ora to be more effective than 0.12% CHX in reducing the mean GI and PI scores among all the 3 groups.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106239 | PMC |
| http://dx.doi.org/10.4103/jomfp.jomfp_368_21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravascular Imaging as a Performance Measure for Percutaneous Coronary Intervention.
Circ Cardiovasc Interv
January 2025
Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle (E.J.S., T. Salahuddin, J.A.D.).
Background: Intravascular imaging (IVI) is widely recognized to improve outcomes after percutaneous coronary intervention (PCI). However, IVI is underutilized and is not yet established as a performance measure for quality PCI.
Methods: We examined temporal trends of IVI use for all PCIs performed at Veterans Affairs hospitals in the United States from 2010 to 2022 using retrospective observational cohorts.
The Kidney-Immune-Brain Axis: The Role of Inflammation in the Pathogenesis and Treatment of Stroke in Chronic Kidney Disease.
Stroke
January 2025
Wolfson Centre for the Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom. (D.M.K., P.M.R.).
Cardiovascular diseases such as stroke are a major cause of morbidity and mortality for patients with chronic kidney disease (CKD). The underlying mechanisms connecting CKD and cardiovascular disease are yet to be fully elucidated, but inflammation is proposed to play an important role based on genetic association studies, studies of inflammatory biomarkers, and clinical trials of anti-inflammatory drug targets. There are multiple sources of both endogenous and exogenous inflammation in CKD, including increased production and decreased clearance of proinflammatory cytokines, oxidative stress, metabolic acidosis, chronic and recurrent infections, dialysis access, changes in adipose tissue metabolism, and disruptions in intestinal microbiota.
View Article and Find Full Text PDFProgressive systemic inflammation precedes decompensation in compensated cirrhosis.
JHEP Rep
February 2025
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Instituto Ramon y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.
Background & Aims: Systemic inflammation is a driver of decompensation in cirrhosis with unclear relevance in the compensated stage. We evaluated inflammation and bacterial translocation markers in compensated cirrhosis and their dynamics in relation to the first decompensation.
Methods: This study is nested within the PREDESCI trial, which investigated non-selective beta-blockers for preventing decompensation in compensated cirrhosis and clinically significant portal hypertension (CSPH: hepatic venous pressure gradient ≥10 mmHg).
The prevalence of hypermobile Ehlers-Danlos syndrome at a gender-affirming primary care clinic.
SAGE Open Med
January 2025
Tufts University School of Medicine, Boston, MA, USA.
Objective: This study utilized a sample of trangender, nonbinary, and gender-diverse (TGD) patients to build on emerging literature that suggests that hypermobile Ehlers-Danlos syndrome may be overrepresented in TGD populations. The objective of this retrospective chart review was to determine the prevalence of hypermobile Ehlers-Danlos syndrome syndrome at a gender-affirming primary care clinic.
Methods: A retrospective chart review of medical records was conducted with records between May 2021 and June 2024.
Evaluation of liver fibrosis in HCV-infected patients using two-dimensional shear-wave elastography (2D-SWE) before and after antiviral treatment.
J Ultrason
December 2024
Department of General and Pediatric Radiology, Wrocław Medical University, Wrocław, Poland.
Aim: Chronic hepatitis C virus infections can lead to liver fibrosis. Appropriate treatment of chronic hepatitis C may result in significant fibrosis reversal. The best method to assess liver fibrosis is an invasive hepatic biopsy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!